[Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)].
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy; D002545:Brain Ischemia / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D004617:Embolism / Q000209:etiology* / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D054833:Isoindoles; D007558:Italy; D008297:Male; D008875:Middle Aged; D010654:Phenylbutyrates / Q000008:administration & dosage / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
D000925:Anticoagulants; D054833:Isoindoles; D010654:Phenylbutyrates; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; C020371:indobufen; D001241:Aspirin